BXCL701, immune checkpoint inhibitors combo holds promise for castration-resistant prostate cancer patients April 21, 2017 Combining BioXcel‘s BXCL701 with immune checkpoint inhibitors may potentially help treat men with castration-resistant prostate cancer (CRPC), says the Branford, Conn., pharma company.Read more. Source: Prostate Cancer News Today About Prostate Cancer Prostate Cancer News Treatment Options More for you
Combining BioXcel‘s BXCL701 with immune checkpoint inhibitors may potentially help treat men with castration-resistant prostate cancer (CRPC), says the Branford, Conn., pharma company.Read more. Source: Prostate Cancer News Today
Donate Now
